Qiagen NV (QGEN) Stock

To promote internal growth, QIAGEN is making significant investments in research and development to broaden the range of its main platforms.

No matter if you invest in value, growth, or momentum stocks, the Zacks Style Scores can help you identify strong stocks more easily. This is one of the key features of the Zacks Premium research service.

The Zacks Style Scores help investors quickly identify highly-rated stocks that match their investment preferences. Here are some reasons to make the most of this tool.

QGEN has reached an important milestone by placing over 1,000 EZ2 Connect devices around the world, which adds to a total of more than 5,500 EZ series instruments in use globally.

QGEN's strong growth in its testing options and possibilities in molecular diagnostics look promising for investors.

QIAGEN's new location in Barcelona is expected to boost the growth of QIAstat-Dx in the areas of infectious diseases and precision medicine testing.

QIAGEN has launched two new customizable tools for designing dPCR assays, which use advanced algorithms suited for various microbial uses and personalized NGS panels.

QIAGEN has revealed its intention to relocate its QIAstat-Dx operations to a new facility in Esplugues de Llobregat, near Barcelona, as part of a long-term investment to enhance this sector of the business. The new site is expected to be operational by early 2026 and will encompass the complete value chain for the QIAstat-Dx system, which is designed for syndromic testing to determine the cause of illnesses.

The Zacks Style Scores help investors quickly identify highly-rated stocks that match their investment preferences. Here are some reasons to make the most of this tool.